Aprea Therapeutics Inc at 38th Annual J.P Morgan Healthcare Conference Transcript
Good afternoon. I'm Jess Fye, one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference this afternoon with Aprea. We're going to do a quick Q&A session with the management team right after this presentation ends. It's going to be just down the hall in the Yorkshire room. But for the presentation, I'm going to turn it over to the company's CEO, Chris Schade.
Thank you, Jess, and thank you for JPMorgan for inviting us to the conference, and thank you all for attending the presentation today. What I'd like to do today is sort of give you an update of the considerable progress that Aprea is making in its own clinical program to advance the very first p53 reactivator into commercialization. So we've made considerable progress in this field in MDS, myeloid disease and AML, and we're now branching off into different disease indications as well. So today, we'll give you a good
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |